Radio Electric Asymmetric Conveyer Technology Modulates Neuroinflammation in a Mouse Model of Neurodegeneration

Abstract

In this study, the effects of Radio Electric Asymmetric Conveyer (REAC), a non-invasive physical treatment, on neuroinflammatory responses in a mouse model of parkinsonism induced by intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were investigated in vivo. We found that the REAC tissue optimization treatment specific for neuro-regenerative purposes (REAC TO-RGN-N) attenuated the inflammatory picture evoked by MPTP-induced nigro-striatal damage in mice, decreasing the levels of pro-inflammatory molecules and increasing anti-inflammatory mediators. Besides, there was a significant reduction of both astrocyte and microglial activation in MPTP-treated mice exposed to REAC TO-RGN-N. These results indicated that REAC TO-RGN-N treatment modulates the pro-inflammatory responses and reduces neuronal damage in MPTP-induced parkinsonism.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. 1.

    González-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999, 22: 219–240.

    Article  PubMed  Google Scholar 

  2. 2.

    Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang K-C, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 2004, 25: 663–674.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Chen Z, Zhong C. Oxidative stress in Alzheimer’s disease. Neurosci Bull 2014, 30: 271–281.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Su F, Bai F, Zhang Z. Inflammatory cytokines and Alzheimer’s disease: a review from the perspective of genetic polymorphisms. Neurosci Bull 2016, 32: 469–480.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Eder C. Regulation of microglial behavior by ion channel activity. J Neurosci Res 2005, 81: 314–321.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Jurgens HA, Johnson RW. Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. Exp Neurol 2012, 233: 40–48.

    Article  PubMed  Google Scholar 

  7. 7.

    Kingwell K. Neurodegenerative disease: Microglia in early disease stages. Nat Rev Neurol 2012, 8: 475.

    Article  PubMed  Google Scholar 

  8. 8.

    Yuan H, Zheng JC, Liu P, Zhang SF, Xu JY, Bai LM. Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes. Neurosci Bull 2007, 23: 125–130.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Yuan H, Zhang ZW, Liang LW, Shen Q, Wang XD, Ren SM, et al. Treatment strategies for Parkinson’s disease. Neurosci Bull 2010, 26: 66.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 2013, 3: 1393.

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, et al. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011, 18: 79–88.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Panaro MA, Lofrumento DD, Saponaro C, De Nuccio F, Cianciulli A, Mitolo V, et al. Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson’s-like disease. Immunopharmacol Immunotoxicol 2008, 30: 729–740.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Collodel G, Fioravanti A, Pascarelli NA, Lamboglia A, Fontani V, Maioli M, et al. Effects of regenerative radioelectric asymmetric conveyer treatment on human normal and osteoarthritic chondrocytes exposed to IL-1B: A biochemical and morphological study. Clin Interv Aging 2013, 8: 309–316.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Gualini S, et al. Radiofrequency energy loop primes cardiac, neuronal, and skeletal muscle differentiation in mouse embryonic stem cells: A new tool for improving tissue regeneration. Cell Transplant 2012, 21: 1225–1233.

    Article  PubMed  Google Scholar 

  15. 15.

    Rinaldi S, Maioli M, Santaniello S, Castagna A, Pigliaru G, Gualini S, et al. Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study. Clin Interv Aging 2012, 7: 191–194.

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Delitala A, et al. Radioelectric asymmetric conveyed fields and human adipose-derived stem cells obtained with a nonenzymatic method and device: a novel approach to multipotency. Cell Transplant 2014, 23: 1489–1500.

    Article  PubMed  Google Scholar 

  17. 17.

    Mura M, Castagna A, Fontani V, Rinaldi S. Preliminary pilot fMRI study of neuropostural optimization with a noninvasive asymmetric radioelectric brain stimulation protocol in functional dysmetria. Neuropsychiatr Dis Treat 2012, 8: 149–154.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Rinaldi S, Fontani V, Castagna A. Brain activity modification produced by a single radioelectric asymmetric brain stimulation pulse: a new tool for neuropsychiatric treatments. Preliminary fMRI study. Neuropsychiatr Dis Treat 2011, 7: 649–654.

    Article  PubMed  Google Scholar 

  19. 19.

    Rinaldi S, Fontani V, Moretti E, Rosettani B, Aravagli L, Saragò G, et al. A new approach on stress-related depression & anxiety: Neuro-Psycho- Physical-Optimization with Radio Electric Asymmetric-Conveyer. Indian J Med Res 2010, 132: 189–194.

    PubMed  Google Scholar 

  20. 20.

    Rinaldi S, Fontani V, Aravagli L, Margotti ML. Psychological and symptomatic stress-related disorders with radio-electric treatment: psychometric evaluation. Stress Heal 2010, 26: 350–358.

    Article  Google Scholar 

  21. 21.

    Rinaldi S, Fontani V, Mannu P, Castagna A. Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline. Patient Prefer Adherence 2011, 5: 581–586.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Rinaldi S, Fontani V, Aravagli L, Mannu P, Castagna A, Lotti M. Noninvasive radioelectric asymmetric brain stimulation in the treatment of stress-related pain and physical problems: psychometric evaluation in a randomized, single-blind placebo-controlled, naturalistic study. Int J Gen Med 2011, 4: 681–686.

    Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Rinaldi S, Mannu P, Fontani V, Castagna A. Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor. Neuropsychiatr Dis Treat 2011, 7: 373–379.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Olivieri EB, Vecchiato C, Ignaccolo N, Mannu P, Castagna A, Aravagli L, et al. Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study. Neuropsychiatr Dis Treat 2011, 7: 449–455.

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Rinaldi S, Fontani V, Aravagli, Lotti M, Castagna A, Piero Mannu. Neuropsychophysical optimization by REAC technology in the treatment of: sense of stress and confusion. Psychometric evaluation in a randomized, single blind, sham-controlled naturalistic study. Patient Prefer Adherence 2012, 6: 195–199.

  26. 26.

    Rinaldi S, Mannu P, Fontani V, Castagna A. Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease. Clin Interv Aging 2011, 6: 207–211.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Olazarán J, González B, López-Álvarez J, Castagna A, Osa-Ruiz E, Herrero-Cano V, et al. Motor effects of REAC in advanced Alzheimer’s disease: results from a pilot trial. J Alzheimers Dis 2013, 36: 297–302.

    PubMed  Google Scholar 

  28. 28.

    Luca L, Alessandro G, Sandra S, Antonio BV, Mercedes F, Matteo LM, et al. REAC technology modifies pathological neuroinflammation and motor behaviour in an Alzheimer’s disease mouse model. Sci Rep 2016, 6: 35719.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Delitala A, et al. Anti-senescence efficacy of radio-electric asymmetric conveyer technology. Age (Omaha) 2014, 36: 9–20.

    CAS  Article  Google Scholar 

  30. 30.

    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Gualini S, et al. Radio electric conveyed fields directly reprogram human dermal skin fibroblasts toward cardiac, neuronal, and skeletal muscle-like lineages. Cell Transplant 2013 22: 1227–1235.

    Article  PubMed  Google Scholar 

  31. 31.

    Maioli M, Rinaldi S, Migheli R, Pigliaru G, Rocchitta G, Santaniello S, et al. Neurological morphofunctional differentiation induced by REAC technology in PC12. A neuro protective model for Parkinson’s disease. Sci Rep 2015, 5: 10439.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Rinaldi S, Maioli M, Pigliaru G, Castagna A, Santaniello S, Basoli V, et al. Stem cell senescence: Effects of REAC technology on telomerase-independent and telomerase-dependent pathways. Sci Rep 2014, 4: 6373.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Rinaldi S, Mura M, Castagna A, Fontani V. Long-lasting changes in brain activation induced by a single REAC technology pulse in Wi-Fi bands. Randomized double-blind fMRI qualitative study. Sci Rep 2014, 4: 5668.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Zippo AG, Rinaldi S, Pellegata G, Caramenti GC, Valente M, Fontani V, et al. Electrophysiological effects of non-invasive Radio Electric Asymmetric Conveyor (REAC) on thalamocortical neural activities and perturbed experimental conditions. Sci Rep 2015, 5: 18200.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2007, 2: 141–151.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Panaro MA, Carofiglio V, Calvello C, Aloisi A, Rinaldi R, Nicolardi G, et al. Modulation of pro-inflammatory response in a mouse model of Parkinson’s disease by non-invasive physical approach: preliminary evaluation. Proc 2015 IEEE 15th Mediterr Microw Symp 2015: 1–4.

  37. 37.

    Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46: 598–605.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Miller KM, Okun MS, Marsiske M, Fennell EB, Bowers D. Startle reflex hyporeactivity in Parkinson’s disease: An emotion-specific or arousal-modulated deficit? Neuropsychologia 2009, 47: 1917–1927.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003, 39: 889–909.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 2004, 10: S3–7.

    Article  PubMed  Google Scholar 

  41. 41.

    Gao HM. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. FASEB J 2003, 17: 1957–1959.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells. J Neural Transm Suppl 2006, 71: 53–65.

    CAS  Article  Google Scholar 

  43. 43.

    Panaro MA, Cianciulli A. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease. Curr Pharm Des 2012, 18: 200–208.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Doherty GH. Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories. Neurosci Bull 2011, 27: 366–382.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Kurkowska-Jastrzębska I, Wrońska A, Kohutnicka M, Członkowski A, Członkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156: 50–61.

    Article  PubMed  Google Scholar 

  46. 46.

    Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson’s disease. J Neural Transm Suppl 2000, 54: 143–151.

    Google Scholar 

  47. 47.

    Mandel S, Weinreb O, Youdim MB. Using cDNA microarray to assess Parkinson’s disease models and the effects of neuroprotective drugs. Trends Pharmacol Sci 2003, 24: 184–191.

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16: 724–739.

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001, 21: 6480–6491.

    CAS  PubMed  Google Scholar 

  50. 50.

    Bal-Price A, Matthias A, Brown GC. Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production. J Neurochem 2002, 80: 73–80.

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD, Dexter DT. Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med 2011, 50: 633–640.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Gahm C, Holmin S, Wiklund PN, Brundin L, Mathiesen T. Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion. J Neurotrauma 2006, 23: 1343–1354.

    Article  PubMed  Google Scholar 

  53. 53.

    Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007, 100: 1375–1386.

    CAS  Article  PubMed  Google Scholar 

  54. 54.

    Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol 2007, 205: 295–312.

    CAS  Article  PubMed  Google Scholar 

  55. 55.

    Molina-Holgado F, Grencis R, Rothwell NJ. Actions of exogenous and endogenous IL-10 on glial responses to bacterial LPS/cytokines. Glia 2001, 33: 97–106.

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Cianciulli A, Dragone T, Calvello R, Porro C, Trotta T, Lofrumento DD, et al. IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. Int Immunopharmacol 2015, 24: 369–376.

    CAS  Article  PubMed  Google Scholar 

  57. 57.

    Stoll G, Jander S, Schroeter M. Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl 2000, 59: 81–89.

    CAS  PubMed  Google Scholar 

  58. 58.

    Calvello R, Cianciulli A, Nicolardi G, De Nuccio F, Giannotti L, Salvatore R. Vitamin D treatment attenuates neuroinflammation and dopaminergic neurodegeneration in an animal model of Parkinson’s disease, Shifting M1 to M2 microglia responses. J Neuroimmune Pharmacol 2017, 12: 327–339.

    Article  PubMed  Google Scholar 

  59. 59.

    Dragone T, Cianciulli A, Calvello R, Porro C, Trotta T, Panaro MA. Resveratrol counteracts lipopolysaccharide-mediated microglial inflammation by modulating a SOCS-1 dependent signaling pathway. Toxicol In Vitro 2014, 28: 1126–1135.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Lofrumento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, Carofiglio V, et al. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun 2014, 20: 249–260.

    Article  PubMed  Google Scholar 

  61. 61.

    Qin H, Niyongere SA, Lee SJ, Baker BJ, Benveniste EN. Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immuno 2008, 181: 3167–3176.

    CAS  Article  Google Scholar 

  62. 62.

    Sedeño-Monge V, Arcega-Revilla R, Rojas-Morales E, Santos-López G, Perez-García JC, Sosa-Jurado F, et al. Quantitative analysis of the suppressors of cytokine signaling 1 and 3 in peripheral blood leukocytes of patients with multiple sclerosis. J Neuroimmunol 2014, 273: 117–119.

    Article  PubMed  Google Scholar 

  63. 63.

    Guedes JR, Custodia CM, Silva RJ, de Almeida LP, Pedroso de Lima MC, Cardoso AL. Early miR-155 upregulation contributes to neuroinflammation in Alzheimer’s disease triple transgenic mouse model. Hum Mol Gene 2014, 23: 6286–6301.

    CAS  Article  Google Scholar 

  64. 64.

    Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006, 7: 148–155.

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Jung DY, Lee H, Jung BY, Ock J, Lee MS, Lee WH, et al. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. J Immunol 2005, 174: 6467–6476.

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Liu HY, Chen CY, Hsueh YP. Innate immune responses regulate morphogenesis and degeneration: roles of Toll-like receptors and Sarm1 in neurons. Neurosci Bull 2014, 30: 645–654.

    Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Trotta T, Porro C, Calvello R, Panaro MA. Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol 2014, 268: 1–12.

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, et al. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern. Neurobiol Aging 2009, 30: 759–768.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Mr. Diego Mangiullo for technical assistance in animal cage assembly. This work was partially supported by a Fondazione Umberto Veronesi 2011 grant to RR, by a grant from the University of Bari (Fondi di Ateneo 2014), and by a grant from the University of Salento (Fondi di Ateneo 2014).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dario Domenico Lofrumento.

Ethics declarations

Conflict of interest

Salvatore Rinaldi and Vania Fontani are the inventors of REAC technology. They are also founders of the company that produces REAC technology.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Panaro, M.A., Aloisi, A., Nicolardi, G. et al. Radio Electric Asymmetric Conveyer Technology Modulates Neuroinflammation in a Mouse Model of Neurodegeneration. Neurosci. Bull. 34, 270–282 (2018). https://doi.org/10.1007/s12264-017-0188-0

Download citation

Keywords

  • Parkinson’s disease
  • Neurodegeneration
  • Neuroinflammation
  • REAC TO-RGN-N treatment